Visit [ Ссылка ] for more.
Dr Arteaga (Vanderbilt-Ingram Cancer Center, Nashville, USA) talks to ecancertv at SABCS 2014 about negative data out of the phase III ICE trial.
In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy agents, did not improve outcomes when tested as monotherapy.
